Obituaries
PGe
PG Store
Archives
Classifieds
Classified
Events
Jobs
Real Estate
Legal Notices
Pets
MENU
SUBSCRIBE
LOGIN
REGISTER
LOG OUT
MY PROFILE
Home
News
Local
Sports
Opinion
A&E
Life
Business
Contact Us
NEWSLETTERS
MENU
ACCOUNT
Subscribe
Login
Register
Log out
My Profile
Subscriber Services
Search
SECTIONS
HOME
Homepage
This Just In
Chats
Weather
Traffic
Event Guide
PG Store
PGe
Video
Photos
The Digs
RSS Feeds
NEWS
News Home
COVID-19
World
Nation
State
Obituaries
News Obituaries
Politics
Education
Portfolio
Science
Health & Wellness
Environment
Aging Edge
Transportation
Faith & Religion
Crimes & Courts
Social Services
LOCAL
Local Home
Region
City
North
East
West
South
Washington
Westmoreland
The Neighborhood
Obituaries
Classifieds
Legal Notices
Real Estate
SPORTS
Sports Home
Steelers
Penguins
Pirates
Sports Columns
Gene Collier
Ron Cook
Joe Starkey
Paul Zeise
High School Sports
College Sports
Pitt
Penn State
WVU
NCAA
NFL
MLB
NBA
NHL
North Shore Drive Podcast
OPINION
Opinion Home
Editorials
Letters
Op-Ed Columns
PG Columnists
Insight
A&E
A&E Home
Celebrities
Movies
TV & Radio
Music
Concert Listings
Theatre & Dance
Art & Architecture
Books
Events
LIFE
Life Home
Food
Buying Here
Homes & Gardens
Style & Fashion
Travel
Restaurants
Seen
goodness
Random Acts of Kindness
Pets
Beer Me
Outdoors
Holidays
BUSINESS
Business Home
Your Money
Wheels
Workzone
Business Health
Tech News
Building PGH
Powersource
Business / Law
Top Workplaces
Business of Pittsburgh
Consumer Alerts
OTHER
PGe
NEWSLETTERS
PG STORE
ARCHIVES
CLASSIFIEDS
OBITUARIES
JOBS
LEGAL NOTICES
REAL ESTATE
CLASSIFIEDS
EVENTS
PETS
CONTACT US / FAQ
CONTACT US
ADVERTISING
CAREER OPPORTUNITIES
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
AtriCure, Inc. - Common Stock
(NQ:
ATRC
)
48.98
+1.49 (+3.14%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 21, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AtriCure, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
Next >
AtriCure Targets $1 Billion as Pain Management and AFib Trials Fuel Growth
↗
August 11, 2026
AtriCure (NASDAQ:ATRC) said it is seeing continued growth across its atrial fibrillation, left atrial appendage management and postsurgical pain-management businesses, supported by new product...
Via
MarketBeat
Two AtriCure Directors Trimmed Shares After a Strong Quarter. Here's What Matters for Investors
↗
August 07, 2026
The sale came at $38.42 per share, slightly below the day's market close, as AtriCure maintains its $2.0 billion market cap in the medical device sector.
Via
The Motley Fool
Topics
Regulatory Compliance
An AtriCure Director Sold $905,000 in Stock. Here's How to Read It
↗
August 07, 2026
Prange's open-market disposition reduced her direct holdings by 14%, though she retains over 22,800 shares in the $2.0 billion medical device company.
Via
The Motley Fool
Topics
Regulatory Compliance
AtriCure (NASDAQ:ATRC) Profitability Surge Drives After-Hours Rally Despite Inline Revenue
↗
July 23, 2026
Via
Chartmill
AtriCure (NASDAQ:ATRC) Q1 Results Beat Estimates as Company Reaches Key Profitability Milestone
↗
May 05, 2026
Via
Chartmill
AtriCure Inc (NASDAQ:ATRC) Stock Surges on Q4 2025 Earnings Beat and Profitability Milestone
↗
February 17, 2026
Via
Chartmill
Topics
Earnings
AtriCure to Participate at Upcoming Investor Conferences
July 27, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure Q2 Earnings Call Highlights
↗
July 23, 2026
AtriCure (NASDAQ:ATRC) reported double-digit revenue growth and a return to GAAP profitability in the second quarter of 2026, with management pointing to strong demand across its pain management,...
Via
MarketBeat
Topics
Earnings
AtriCure Reports Q2 2026 Results: Full Earnings Call Transcript
↗
July 23, 2026
AtriCure (NASDAQ:ATRC) reported second-quarter financial results on Thursday. The transcript from the company's second-quarter earnings call has been provided below. This transcript is brought to you...
Via
Benzinga
Topics
Earnings
AtriCure Reports Second Quarter 2026 Financial Results
July 23, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure to Announce Second Quarter 2026 Financial Results
July 02, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure to Participate in the Goldman Sachs 47th Annual Global Health Care Conference
May 27, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure Conference: New Devices, EnCompass Drive 2026 Growth Outlook
↗
May 12, 2026
AtriCure (NASDAQ:ATRC) executives said the company’s 2026 revenue outlook is being supported by recent and upcoming product launches, continued adoption of its EnCompass ablation platform and expanding...
Via
MarketBeat
AtriCure (ATRC) Q1 2026 Earnings Transcript
↗
May 06, 2026
AtriCure (ATRC) Q1 2026 Earnings Transcript
Via
The Motley Fool
AtriCure Reports First Quarter 2026 Financial Results
May 05, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure to Participate in the 2026 Bank of America Securities Health Care Conference
April 28, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure to Announce First Quarter 2026 Financial Results
April 14, 2026
From
AtriCure, Inc.
Via
Business Wire
This Biotech Stock Winner Is Up 72%, but a $4 Million Trim Signals a Slight Reset
↗
March 21, 2026
This clinical-stage biotech develops oncology therapies targeting unmet needs in cancer and immune-mediated conditions.
Via
The Motley Fool
Topics
Regulatory Compliance
This $6.5 Million Healthcare Trim Comes Amid a 71% Stock Surge and 20% Revenue Growth
↗
March 21, 2026
This healthcare firm develops advanced surgical solutions for peripheral nerve repair, serving hospitals and specialists worldwide.
Via
The Motley Fool
Topics
Regulatory Compliance
This $8.9 Million Buy Targets a Stock Down 68% With $322 Million in Cash
↗
March 21, 2026
Biohaven develops clinical-stage therapies for neurological and immunoscience disorders, with no commercialized products to date.
Via
The Motley Fool
Topics
Regulatory Compliance
DAFNA Capital Trims iShares Biotechnology ETF Within Broader Biotech Portfolio, According to Recent SEC Filing
↗
March 21, 2026
iShares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but...
Via
The Motley Fool
Topics
Derivatives
ETFs
Regulatory Compliance
AtriCure CSO Sells 5,000 Shares — A Modest Trim or a Pattern Worth Watching?
↗
March 18, 2026
This medical device innovator for cardiac surgery reported a notable insider sale amid a year of negative total returns.
Via
The Motley Fool
Topics
Derivatives
Regulatory Compliance
AtriCure to Participate in the Citizens Life Sciences Conference
February 24, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure (ATRC) Q4 2025 Earnings Call Transcript
↗
February 17, 2026
AtriCure (ATRC) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
AtriCure Reports Fourth Quarter 2025 and Full Year 2025 Financial Results
February 17, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure to Announce Fourth Quarter and Full Year 2025 Financial Results
January 27, 2026
From
AtriCure, Inc.
Via
Business Wire
What's going on in today's pre-market session
↗
January 15, 2026
Via
Chartmill
AI Diagnostics: The End of the High-Cost Imaging Era
January 16, 2026
Issued on behalf of VentriPoint Diagnostics Ltd.
From
Equity Insider
Via
GlobeNewswire
AtriCure Reports Preliminary Results for Fourth Quarter and Full Year 2025, Provides Financial Outlook for 2026
January 12, 2026
From
AtriCure, Inc.
Via
Business Wire
AtriCure to Participate in the J.P. Morgan 44th Annual Healthcare Conference
December 17, 2025
From
AtriCure, Inc.
Via
Business Wire
< Previous
1
2
3
4
5
6
7
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story
Your e-mail:
Friends e-mail:
Submit
